Mode
Text Size
Log in / Sign up
N/A N=200 Randomized Triple-blind Treatment

Penicillin and Metronidazole in Treatment of Peritonsillar Abscess

Peritonsillar Abscess

Enrolled (actual)
200
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Number of Participants With Recurrence of Peritonsillar Abscess — 10; 10 Participants — p=0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
penicillin and metronidazole in peritonsillar abscess (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Helsinki University Central Hospital
Primary completion
Apr 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Recurrence of Peritonsillar Abscess
10; 10 0.05
SECONDARY
Number of Participants Recovering From Peritonsillar Abscess
74; 80 0.05

Summary

Treatment of peritonsillar abscess varies. To study whether broad spectrum antibiotics are required in addition to abscess drainage, a prospective, double blind, placebo-controlled, randomized study on 200 adult patients with peritonsillar abscess is performed. 100 patients are given penicillin and metronidazole and 100 patients get penicillin and placebo. Recovery and recurrence are analyzed.

Eligibility Criteria

Inclusion Criteria

  • referring doctor suspects peritonsillar abscess
  • patient is voluntary
  • patient has daily access to his/her e-mail
  • patient speaks and understands Finnish of Swedish
  • female patients have adequate birth-control method
  • patient has peritonsillar abscess

Exclusion Criteria

  • allergy to penicillin
  • allergy to metronidazole
  • use of metronidazole in preceding one month
  • pregnancy
  • breast-feeding
  • renal insufficiency
  • liver insufficiency
  • alcoholism (drunk at least once a week)
  • participant in another clinical trial at the moment
  • treatment of peritonsillar abscess requires in-patient care
  • tonsillectomy during the next 30 days
  • army recruit
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01255670). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search